It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Coat protein complex I (COP-I) mediates the retrograde transport from the Golgi apparatus to the endoplasmic reticulum (ER). Mutation of the COPA gene, encoding one of the COP-I subunits (α-COP), causes an immune dysregulatory disease known as COPA syndrome. The molecular mechanism by which the impaired retrograde transport results in autoinflammation remains poorly understood. Here we report that STING, an innate immunity protein, is a cargo of the retrograde membrane transport. In the presence of the disease-causative α-COP variants, STING cannot be retrieved back to the ER from the Golgi. The forced Golgi residency of STING results in the cGAS-independent and palmitoylation-dependent activation of the STING downstream signaling pathway. Surf4, a protein that circulates between the ER/ ER-Golgi intermediate compartment/ Golgi, binds STING and α-COP, and mediates the retrograde transport of STING to the ER. The STING/Surf4/α-COP complex is disrupted in the presence of the disease-causative α-COP variant. We also find that the STING ligand cGAMP impairs the formation of the STING/Surf4/α-COP complex. Our results suggest a homeostatic regulation of STING at the resting state by retrograde membrane traffic and provide insights into the pathogenesis of COPA syndrome.
COPA regulates Golgi to ER transport, and mutations lead to autoinflammation and disease through poorly understood mechanisms. Here, the authors show that disease-causing COPA variants prevent STING transport from the Golgi to the ER, leading to cGAS-independent activation of the STING pathway.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Ogawa Emari 2 ; Uematsu Rei 2 ; Kuchitsu Yoshihiko 1 ; Kiku Fumika 2 ; Uemura Takefumi 3 ; Waguri Satoshi 3
; Suzuki, Takehiro 4 ; Dohmae Naoshi 4 ; Arai Hiroyuki 2 ; Shum, Anthony K 5
; Taguchi Tomohiko 1
1 Tohoku University, Laboratory of Organelle Pathophysiology, Department of Integrative Life Sciences, Graduate School of Life Sciences, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943)
2 University of Tokyo, Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
3 Fukushima Medical University School of Medicine, Department of Anatomy and Histology, Fukushima, Japan (GRID:grid.411582.b) (ISNI:0000 0001 1017 9540)
4 RIKEN Center for Sustainable Resource Science, Biomolecular Characterization Unit, Wako, Japan (GRID:grid.7597.c) (ISNI:0000000094465255)
5 University of California San Francisco, Department of Medicine, Division of Pulmonary and Critical Care, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)




